Clinical Research Directory
Browse clinical research sites, groups, and studies.
RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients
Sponsor: Prince of Wales Hospital, Shatin, Hong Kong
Summary
The objective of this study is to conduct a pragmatic, randomized, double-blind, active-controlled trial to assess the efficacy of receptor activator of nuclear factor-kB ligand (RANKL) inhibition in the treatment of sarcopenia in hip fractures.
Official title: RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients: A Pragmatic, Randomized Double-blind, Active-Controlled Trial
Key Details
Gender
All
Age Range
65 Years - Any
Study Type
INTERVENTIONAL
Enrollment
130
Start Date
2026-01-01
Completion Date
2030-01-01
Last Updated
2025-07-09
Healthy Volunteers
No
Conditions
Interventions
Denosumab (Prolia)
60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly
Zoledronic acide (Aclasta)
5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months
Locations (1)
The Chinese University of Hong Kong
Hong Kong, China